• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Surgery Classics

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

byAndrew Cheung, MD MBA
July 11, 2013
in Surgery Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Prostatectomy did not significantly reduce all-cause mortality or prostate-cancer mortality when compared to observation

2. These findings support conservative management for men with localized prostate cancer, especially for those with PSA values less than 10 ng/mL and low-risk disease

Original Date of Publication: July 19, 2012

Study Rundown: The incidence of prostate cancer in men is relatively high, but high long-term survival rates have been observed with conservative management. The treatment of localized prostate cancer is controversial as few trials have compared surgical intervention to observation in the time since prostate specific antigen (PSA) testing has become a common screening tool. This study found no significant difference in all-cause or prostate-cancer mortality following radical prostatectomy compared to observation. These findings suggest that observation is a safe strategy in managing localized prostate cancer and avoids the unnecessary risks of intervention. The results also show that PSA levels and tumour risk may be useful in identifying patients who will benefit from radical prostatectomy. Strengths of the study include the representative sample and measurement of all-cause mortality as the primary outcome which avoids biased assessments of cause-of-death. Of note, the study may have been underpowered as the investigators intended to enroll 2,000 participants, but reduced the sample size to 731. In addition, a substantial number of patients did not adhere to the assigned treatment in both groups, which could influence the observed treatment effect.

Please click to read study in NEJM

RELATED REPORTS

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

2 Minute Medicine Rewind February 16, 2026

AstraZeneca moves to own multimodal oncology AI with Modella

In-Depth [randomized, controlled study]: Published in NEJM in 2012, this randomized controlled trial assessed the effectiveness of surgery versus observation for men with localized prostate cancer. The trial included 731 men and followed participants for a median of 10 years. The primary outcome was all-cause mortality and a secondary outcome was prostate-cancer mortality, defined as death due to prostate cancer or prostate cancer treatment. The rate of all-cause mortality was not significantly different between the two groups with an absolute risk reduction of 2.9 percentage points in the radical-prostatectomy group. There was also no significant difference between groups in prostate cancer mortality. A significant interaction was found between study group and baseline PSA value. In men with a PSA value greater than 10 ng/mL, a significant reduction in all-cause mortality was observed with surgery, though surgery did not reduce all-cause mortality in men with a PSA less than or equal to 10 ng/mL.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: canceroncologyPIVOTprostateprostatectomy
Previous Post

Alternative treatment for acute promyelocytic leukemia promising

Next Post

African Americans, obese overrepresented in young heart failure cases

RelatedReports

2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

February 20, 2026
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026
Patients with advanced adenomas are at increased risk of developing colorectal cancer
AI Roundup

AstraZeneca moves to own multimodal oncology AI with Modella

January 21, 2026
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026]

January 19, 2026
Next Post
Gestational weight loss may improve outcomes for obese women

African Americans, obese overrepresented in young heart failure cases

Everolimus only protects against early cardiac allograft vasculopathy

Antibiotic implants reduce surgical site infections

Preterm delivery associated with long-term maternal cardiovascular risk

Preterm delivery associated with long-term maternal cardiovascular risk

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]
  • Virtual reality rehabilitation is safe and feasible for upper extremity recovery after subacute ischemic stroke
  • Safety and efficacy of novel antibody-oligonucleotide therapy for myotonic dystrophy type 1
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.